Restoring neural networks

Erika R. Smith, CEO
esmith@renetx.com
ReNetX Bio: Clinical stage company
Significant Opportunity for Patients and Partners

Leadership Expertise
Extensive experience in building & exiting biotech investments; Raised $30M with vetted partners

Technology/IP
Yale Innovation; extensive issued worldwide patents; new IP filed & actively in process; additional 12 years of regulatory exclusivity with BLA

Unmet Market Need
Pipeline >$5B indications across neurology & ophthalmology

Significant Return
Support from global biotech; Key Exit Inflection Point with data readout in early 2022
What is the Problem We’re Solving?
ReNetX Approach: Block Axonal Growth Inhibitors in the CNS to Promote Neural Repair

Nogo-A, MAG, OMgp bind to NgR1 preventing axonal growth

AXER-204 prevents binding with broader targets than single antibodies.

AXER-204 promotes new neural connections through axonal sprouting, axonal regeneration, and synaptogenesis
Optic Nerve Axonal Growth

Control – NO growth post injury

Axonal growth post-injury with treatment

Axonal growth post-injury with treatment

Scale bar: 500 µm
The ReNetX Difference

**Insults to the Nervous System**
- Inflammation
- Intraocular pressure
- Trauma
- Metabolic/Toxins

**AXON LOSS**

**Diseases**
- Multiple Sclerosis
- Neurodegenerative Diseases
- Optic Nerve Damage (Glaucoma/Optic Neuritis, etc)
- Traumatic injuries

**ReNetX Next Generation Therapy**
- Changing the underlying environment in the CNS promoting regrowth.
- Synergistic with existing therapies.
- Strong safety profile – no off-target effects
<table>
<thead>
<tr>
<th>Model Type</th>
<th>Species</th>
<th>Endpoints</th>
<th>Institutions</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute SCI, Transection</td>
<td>Rat</td>
<td>Axonal growth</td>
<td>Univ. of Toronto</td>
<td>Guo et al, Cell Transplant. 2012 Jan 10. epub ahead of print</td>
</tr>
<tr>
<td>Advisory Board Leadership</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Stephen Strittmatter, MD, PhD</strong>&lt;br&gt;Founder, Chief Scientific &amp; Medical Advisor</td>
<td>Recognized key opinion leader in neuro-regeneration &amp; neuro-degeneration from Yale University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Daniel Lammertse, MD</strong>, Medical Director (ret.); Craig Hospital</td>
<td>30+ years managing a leading rehabilitation center &amp; supporting all key SCI trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Andrew Blight, PhD</strong>, CSO (ret.)&lt;br&gt;Acorda (NASDAQ: ACOR)</td>
<td>Career leadership in neurology-based innovation with extensive experience in SCI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Jeffrey Goldberg, MD, PhD</strong>, Professor &amp; Chair of Ophthalmology, Byers Eye Institute; Stanford University</td>
<td>Key opinion leader in glaucoma innovation &amp; biomarker strategies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Jim Tsai, MD, MBA</strong>, President, New York Eye &amp; Ear Infirmary of Mt. Sinai</td>
<td>Delafield-Rodgers Professor &amp; System Chair, Dept. of Ophthalmology; Icahn School of Medicine at Mount Sinai</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Kevin Malobisky, PhD</strong>, Chief Regulatory &amp; Strategic Operations Officer, Tavanta</td>
<td>Previously led the Achillion team to FDA breakthrough therapy &amp; $1B acquisition to Alexion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The 2017 Blavatnik Award winners flanked by Erika Smith, Director of the Innovation Fund & Yale President Peter Salovey
The RESET Clinical Trial

Objectives: To evaluate the safety, pharmacokinetics & efficacy of AXER-204 in participants with chronic cervical SCI having significant but incomplete impairment of hand & arm function

Part 1: Single Ascending Dose
- Four cohorts
- Each successive cohort receives a higher single dose
- Part 1 Complete

Part 2: Repeat Dose
- Dose and frequency of dosing based on data from Part 1
- Data Readout in Early 2022

The Trial will test:
- Safety & tolerability
- Hand & arm function changes
- Changes in ability to perform daily living activities
- Pharmacokinetics
- Antidrug antibodies
- Potential biomarkers

Results so far:
- Strong safety profile
- Trending efficacy
- Biomarkers of target engagement and axonal growth

https://clinicaltrials.gov/ct2/show/NCT03989440
# Extensive Pipeline Opportunity

## NgR1 Platform

### NEUROSCIENCE

<table>
<thead>
<tr>
<th>Indication</th>
<th>Research</th>
<th>Preclinical</th>
<th>IND/Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPINAL CORD INJURY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AXER-204</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STROKE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MULTIPLE SCLEROSIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER CNS AXONAL INJURIES &amp; DISEASES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FDA Fast Track:** [https://clinicaltrials.gov/ct2/show/NCT03989440](https://clinicaltrials.gov/ct2/show/NCT03989440)

### OPHTHALMOLOGY

<table>
<thead>
<tr>
<th>Indication</th>
<th>Research</th>
<th>Preclinical</th>
<th>IND/Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLAUCOMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPTIC NEURITIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER DISORDERS WITH OPTIC NERVE INJURY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ReNetX Bio: Clinical stage company
Significant Opportunity for Patients and Partners

Leadership Expertise
Extensive experience in building & exiting biotech investments; Raised $30M with vetted partners

Technology/IP
Yale Innovation; Extensive issued worldwide patents, new IP filed and actively in process; additional 12 years of regulatory exclusivity with BLA

Unmet Market Need
$5B indications across neurology & ophthalmology

Significant Return
Support from global biotech; Key Exit Inflection Point with data readout in early 2022

Let's talk about partnerships & funding
esmith@renetx.com